Home Tags Ovarian cancer

Tag: ovarian cancer

Mirvetuximab Soravtansine Demonstrates Overall Survival Benefit in FRα-Positive Platinum-Resistant Ovarian Cancer

Positive top-line data from the Phase 3 confirmatory MIRASOL trial (NCT04209855; GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of mirvetuximab soravtansine-gynx compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.

ImmunoGen Submits Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer

Immunogen has submitted a Biologics License Application (BLA) under the accelerated approval pathway to the US Food and Drug Administration (FDA) for mirvetuximab soravtansine...

STRO-002 Shows 33% Objective Response Rate in Patients with Advanced Ovarian...

Folate receptor alpha (FolRα) is a folate-binding protein overexpressed on ovarian and several other epithelial malignancies that can be used as a target for...

ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in...

Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an ongoing expansion study evaluating XMT-1536...

ESMO 2020: XMT-1536 Shows 34% ORR in Phase I Expansion Study...

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536...

ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent...

Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853), in combination with bevacizumab (Avastin®;...

Phase I Dose Escalation Study with Mersana’s XMT-1592 Doses First Patient

Clinical-stage biopharmaceutical company Mersana Therapeutics has confirmed that a first patient has been dosed in a Phase I dose-escalation study evaluating XMT-1592. XMT-1592 is the...

Mersana Reports Updated Data from the XMT-1536 Phase I Dose Escalation...

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer...

The full data and exploratory analyses from the Phase III FORWARD I study (NCT02631876) evaluating mirvetuximab soravtansine, also known as IMGN853, compared to chemotherapy...

Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...

Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...

X